Article Text

Download PDFPDF
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology
  1. William G Dixon1,
  2. Loreto Carmona2,
  3. Axel Finckh3,
  4. Merete Lund Hetland4,
  5. Tore K Kvien5,
  6. Robert Landewe6,
  7. Joachim Listing7,
  8. Paulo J Nicola8,
  9. Ulrik Tarp9,
  10. Angela Zink7,
  11. Johan Askling10
  1. 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, UK
  2. 2Research Unit, Fundación Española de Reumatología, Madrid, Spain
  3. 3SCQM Foundation, Geneva University Hospital, Geneva, Switzerland
  4. 4DANBIO, Department of Rheumatology, Hvidovre and Glostrup Hospitals, University of Copenhagen, Copenhagen, Denmark
  5. 5Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
  6. 6Maastricht University Medical Center, Maastricht, The Netherlands
  7. 7Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany
  8. 8Epidemiology Unit, Institute for Preventive Medicine, University of Lisbon Medical School, Lisbon, Portugal
  9. 9Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
  10. 10Department of Rheumatology, Karolinska University Hospital and Institute, Stockholm, Sweden
  1. Correspondence to William G Dixon, Arthritis Research UK Epidemiology Unit, The University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK; will.dixon{at}manchester.ac.uk

Footnotes

  • Competing interests None. Johannes WJ Bijlsma was the handling editor for this manuscript.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests None. Johannes WJ Bijlsma was the handling editor for this manuscript.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.